| Trial | Treatments | Patients | Method |
|---|
| EMPA-REG OUTCOME, 2015 | 10 mg or 25 mg of empagliflozin once daily (n=4687) vs. placebo (n=2333) | patients
with type 2 diabetes at high cardiovascular risk | double-blind Parallel groups Sample size: 4687/2333 Primary endpoint: death from cardiovascular FU duration: 3.1 years (median) |
| EMPA-REG OUTCOME | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Barnett, 2014 | / BI 10773 low dose (BI 10773 tablets once daily)
2/ BI 10773 high dose (BI 10773 tablets once daily)
(n=-9) vs. Placebo (n=-9) | Patients With Mild or Moderate Renal Impairment | Sample size: -9/-9 Primary endpoint: HbA1c Change , , FU duration: |
| Araki, 2015 | BI 10773 low dose (BI 10773 low dose tablet once daily)
2/ BI 10773 high dose (BI 10773 high dose tablet once daily)
(n=-9) vs. Metformin (Metformin tablets 500-2250 mg a day (twice or three times per day)) (n=-9) | Japanese patients with type 2 diabetes mellitus | Sample size: -9/-9 Primary endpoint: Drug Related Adverse Events FU duration: 52 w |
| Rosenstock (1245.49), 2014 | once-daily empagliflozin 10 mg (n = 186), empagliflozin 25 mg (n = 189), (n=-9) vs. placebo (n=-9) | Patients inadequately controlled on MDI insulin ± metformin | Sample size: -9/-9 Primary endpoint: FU duration: 18 weeks |
| Ridderstrale, 2014 | BI 10773 dose plus metformin (n=-9) vs. Glimepiride 1-4 mg plus metformin (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: 104 w |
| DeFronzo, 2015 | (n=-9) vs. add-on to metformin for 52 weeks (n=-9) | subjects with type 2 diabetes inadequately controlled on metformin | Sample size: -9/-9 Primary endpoint: , FU duration: |
| Lewin, 2015 | empagliflozin 25 mg/linagliptin 5 mg (n = 137), empagliflozin 10 mg/linagliptin 5 mg (n = 136), empagliflozin 25 mg (n = 135), empagliflozin 10 mg (n = 134) (n=-9) vs. linagliptin 5 mg (n = 135) for 52 weeks (n=-9)
|
| Sample size: -9/-9 Primary endpoint: FU duration:
|
| Ferrannini, 2013 | empagliflozin 5, 10 or 25 mg once daily (n=-9) vs. placebo (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: phase 2b |
| Kadowaki, 2013 | (n=-9) vs. (n=-9) | Japanese patients with type 2 diabetes | Sample size: -9/-9 Primary endpoint: FU duration: |
| EMPA-REG PIO (Kovacs), 2013 | once daily empagliflozin 10 mg (n = 165), empagliflozin 25 mg (n=-9) vs. add-on to pioglitazone ± metformin (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| EMPA-REG MONO (Roden) vs placebo, 2013 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Rosenstock, 2013 | (n=-9) vs. ??? (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Rosenstock DOUBLON ???, 2013 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Kadowaki, 2015 | empagliflozin (5, 10, 25, or 50 mg) (n=-9) vs. placebo (n=-9) | Japanese patients with type 2 diabetes | Sample size: -9/-9 Primary endpoint: FU duration: |
| Ross, 2015 | empagliflozin 12.5 mg twice daily (n = 219), 25 mg once daily (n = 218), 5 mg twice daily (n = 219) or 10 mg once daily (n = 220), (n=-9) vs. placebo (n=-9) | patients with type 2 diabetes inadequately controlled on metformin | Sample size: -9/-9 Primary endpoint: FU duration: |
| Kadowaki , 2014 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| EMPA-REG MET (Haring), 2014 | empagliflozin 10 mg (n = 217), empagliflozin 25 mg (n = 213), (n=-9) vs. placebo (n=-9) | Patients with HbA1c levels of ¡Ý7% to ¡Ü 10% (¡Ý53 to ¡Ü86 mmol/mol) while receiving metformin (¡Ý1,500 mg/day) | Sample size: -9/-9 Primary endpoint: FU duration: |
